Navigation Links
Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP

Partnering to Fight TB: The Role of a TB Vaccine PDP
An Exhibitor's Workshop at the 2011 AAAS Annual Meeting



Speakers at the workshop will provide an overview of the state of the global TB epidemic and efforts to develop TB vaccines; the role of non-profit product development partnerships such as Aeras; and ways that scientists and researchers can add their voices to a global call for action on TB.


  • Lewellys F. Barker, MD, Senior Medical Advisor, Aeras
  • David Bryden, Senior Program Policy Officer at the Infectious Diseases Society of America's Center for Global Health Policy
  • Claire Wingfield, TB/HIV Project Coordinator at the Treatment Action Group


TB is one of the world's deadliest infectious diseases, killing nearly 2 million men, women and children every year. Despite global efforts to prevent and treat TB, the epidemic is becoming more complex and difficult to diagnose and treat due in large part to the emergence of drug-resistant forms of TB and the emergence of the HIV epidemic. TB is responsible for the majority of AIDS deaths in Africa. The currently available vaccine, BCG, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. New TB vaccines are urgently needed as part of a comprehensive effort to stop TB.


Contact: Annmarie Leadman
Aeras Global TB Vaccine Foundation

Page: 1

Related biology news :

1. October 2008 GEOLOGY and GSA TODAY media highlights
2. Mediator in communication between neurons and muscle cells found
3. December 2008 Geology and GSA Today media highlights
4. December Geosphere media highlights
5. January GEOLOGY media highlights
6. January-February GSA Bulletin media highlights
7. BIO-key(R) Fingerprint Biometrics Media Spotlights
8. February 2009 Geology and GSA Today media highlights
9. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
10. Mass media often failing in its coverage of global warming, says climate researcher
11. Patience pays off with methanol for uranium bioremediation
Post Your Comments:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: